AMSA Pharm-free Scorecard 2010
B West Virginia University School of Medicine
City: Morgantown State: WV

Summary: Overall, West Virginia University School of Medicine has a good policy, and an improvement over their previous evaluation. This new policy is a model for domains related to consulting and scholarships/trainee funds. Consulting relationships require institutional review, approval and either a formal contract or a description to ensure payment is appropriate. The policy does not prohibit participation in "speaker's bureaus," and requires disclosure and approval from the Dean of the faculty member/staff's school, but does provide safeguards in terms of content of the talks thereby increasing this domain's score.  The gifts and meals policy has also been strengthened by prohibiting all gifts and meals regardless of value.

Demographics: On average students spend 60% of their training at West Virginia University Hospitals, 30% at Charleston Area Medical Center, and 10% at City Hospital. Students are instructed to follow submitted policies regardless of site; however it is unclear how the policies apply to faculty and clinical educators at various sites

Updates: This institution submitted new policies for review in the 2012-3 PharmFree Scorecard.  Their grade remains a B although the policy did see improvements in the gifts and meals as well as industry-funded speaking domains.


This institution's evaluation was last updated: 4/9/2013.

Gifts & Meals 3 The policy prohibits all gifts and on-site meals completely regardless of value.
Consulting relationships 3 The policy requires institutional review and approval from the Dean of the faculty member's School.  The policy also requires either a formal contract or a description to ensure payment is appropriate to the services rendered.
Industry-funded speaking relationships 3 Participation in "speaker's bureaus" is not prohibited and the policy requires disclosure and approval from the Dean of the faculty member/staff's School. Lecture material must be decided by the speaker and not the industrial sponsor.
Disclosure 2 The policy requires internal disclosure from all personnel on an annual basis and states, "such ties are to be posted on a publicly available website, and faculty and staff are to disclose such relationships to patients when such a relationship might represent an apparent conflict of interest."  This policy could be stronger with a mandate for public disclosure.
Pharmaceutical samples 2 The policy requires the acceptance of samples by a centralized pharmacy.  This does not substantially limit the use of samples as a marketing tool since patient access to samples is not limited.
Purchasing & Formularies 2 Committee members are required to disclose their financial conflicts of interest and recusal from committee decisions is limited to a public contract with a company of financial interest.
Industry Sales Representatives 2 Industry sales representatives are allowed in patient care areas under limited circumstances and at the request of a physician.  Industry sales representatives are permitted in non-patient care areas only by appointment.
On-campus Education 2 The policy cites adherence to ACCME standards for on-site educational activities.
Attendance at Industry-Sponsored Lectures & Meetings Off-Campus 2 The policy requires that legitimate reimbursement be in accordance with the institutional policy, for attendace at off-site events.  Although institutional review is required prior to travel, the policy does not establish limitations on payment.
Industry Support for Scholarships & Funds for Trainees 3 The policy prevents industry from choosing the scholarship recipient and institutional review of industry funds is established in the policy.
Medical school curriculum 3 The curriculum aims to impart an understanding of pharmaceutical marketing and its effect on health care decision-making by physicians.
Do the policies specify an oversight mechanism? Yes The policy established the office of the Dean at the School level or the Chancellor's office is responsible for oversight.
Are there explicit sanctions for noncompliance? Yes

Sanctions referenced

What the results mean...
3Model policy
2Good progress toward model policy
1No policy, or policy unlikely to have a substantial effect on behavior
0Did not report
N/APolicy not relevant to this institution (e.g., does not make purchasing decisions)